Effect of Receptor-Selective Retinoids on Growth and Differentiation Pathways in Mouse Melanoma Cells by Desai, Sejal H. et al.
Marshall University
Marshall Digital Scholar
Biochemistry and Microbiology Faculty Research
5-15-2000
Effect of Receptor-Selective Retinoids on Growth
and Differentiation Pathways in Mouse Melanoma
Cells
Sejal H. Desai
Marshall University
Goran Boskovic
Marshall University, gboskovi@marshall.edu
Linda L. Eastham
Marshall University, lloydl@marshall.edu
Marcia Dawson
Marshall University
Richard M. Niles
Marshall University, niles@marshall.edu
Follow this and additional works at: http://mds.marshall.edu/sm_bm
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Genetic
Processes Commons, Medical Biochemistry Commons, Medical Cell Biology Commons, and the
Oncology Commons
This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in
Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact
zhangj@marshall.edu.
Recommended Citation
Desai SH, Boskovic G, Eastham L, Dawson M, Niles RM (2000) Effect of receptor-selective retinoids on growth and differentiation
pathways in mouse melanoma cells. Biochem Pharmacol 59(10):1265-1275.
 1 
Effect of Receptor-Selective Retinoids on Growth and Differentiation 
Pathways in Mouse Melanoma Cells 
 
Sejal H. Desai1,2, Goran Boskovic1, Linda Eastham1, Marcia Dawson3, and 
Richard M. Niles1* 
 
 
1Department of Biochemistry and Molecular Biology 
 Marshall University School of Medicine 
 Huntington, WV  25755 
 
2Present Address 
  Clontech Corp. 
  Palo Alto, CA  94025 
 
3Molecular Medicine Research Institute 
 325 East Middlefield Road 
 Mountain View, CA  94043 
 
 
Running Title:  Receptor-Selective Retinoids 
 
Classification:  Hormones and Growth Factors 
 
*Corresponding Author 
 Phone: 304-696-7322 
 FAX: 304-696-7253 
 Email: niles@marshall.edu 
 2 
*Abbreviations:  RAR, retinoic acid receptor; RXR, retinoid X receptor; ATRA, all-
trans-retinoic acid; 9CRA, 9-cis-retinoic acid; AP-1, activator protein-1; PKC, 
protein kinase C
 3 
 
ABSTRACT. Treatment of B16 mouse melanoma cells with all-trans-retinoic acid 
(ATRA) results in inhibition of cell proliferation and induction of differentiation.  
Accompanying these events is an induction of RAR expression, an increase in 
protein kinase C (PKC) expression and enhanced activator protein-1 (AP-1) 
transcriptional activity.  These cells constitutively express nuclear retinoic acid 
receptors (RAR)  and  and nuclear retinoid X receptors (RXR) and .  We 
tested the ability of receptor-selective retinoids to induce the biochemical 
changes found in ATRA-treated melanoma cells and also their effectiveness in 
decreasing anchorage-dependent and independent growth. The RXR-selective 
ligand SR11246 was most effective at inhibiting anchorage-dependent growth, 
while the RAR-selective ligand SR11254 was most potent at inhibiting 
anchorage-independent growth.  In contrast, Am580 an RAR-selective ligand, 
was the most effective receptor-selective agonist for inducing RAR mRNA  and 
increasing the amount of PKC protein.  All of the retinoids induced a dose-
dependent increase in AP-1 transcriptional activity with little difference in the 
effectiveness among the receptor-selective retinoids.  A synergistic increase in the 
amount of PKC was found when an RAR-selective agonist was combined with 
an RXR-selective agonist. One possible explanation for this result is that an RXR-
RAR heterodimer in which both receptors are liganded is required for maximum 
expression of this critical component of the ATRA-induced differentiation 
pathway. Our data suggest that synthetic retinoids can preferentially activate 
different growth and differentiation pathways in B16 melanoma cells, most likely 
due to their ability to activate a different subset of  receptors.  
 
KEY WORDS:  receptor-selective retinoids, melanoma, proliferation, 
differentiation 
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Retinoids have been found to inhibit growth and induce differentiation in a 
variety of cancer cell lines [1-5].  These effects are thought to be mediated by 
nuclear receptors which belong to the super-family of steroid/thryoid hormone 
receptors.  There are two major classes of retinoid nuclear receptors, the RARs 
and the RXRs.  The RARs bind ATRA  and 9CRA, while the RXR bind only 9CRA 
[6,7].  There are three subtypes (, , and ) of both the RARs [8-10] and the RXRs 
[11, 12].  These receptors are retinoid-activated transcription factors and act by 
binding to specific DNA sequences termed retinoic acid response elements which 
often consists of a direct repeat of PuG(G,T)TCA with a 1 to 5 base pair spacing 
between the repeats [13-15].  Both RARs and RXRs can form homo (RXR:RXR) or 
hetero (RXR:RAR) dimers, with the heterodimer having greater affinity/stability 
in binding to retinoic acid response elements [16, 17].  RXRs can also form 
heterodimers with other members of the steroid/thryoid superfamily of 
receptors [18-20].  By competing for RXRs, these other receptors can influence 
retinoid-regulated gene transcription.  In addition to ligand, the activity of these 
receptors is also regulated by nuclear co-repressor [21], co-activator [22] and 
integrator [23] proteins. 
 Our laboratory has been studying the ATRA-induced growth arrest and 
differentiation of B16 mouse melanoma cells.  This differentiation is 
characterized by increased melanin production [24], arrest in the G1 phase of the 
cell cycle [25], loss of anchorage-independent growth, and acquisition of cell 
surface NGF receptors [24].  The pathway that leads to this differentiated 
phenotype is not known, but induction of PKC plays a significant role [26].  
Retinoic acid treatment also leads to a 4-fold increase in AP-1 transcriptional 
activity, which in contrast to TPA-induced AP-1 activity, is sustained for at least 
36 h [27].  B16 cells constitutively express RAR and RARmRNA and can be 
induced to express RAR mRNA by treatment with ATRA [28].  They also 
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express RXR and  mRNA, but do not express RXR  [29].  In light of the 
expression of multiple retinoid nuclear receptors, the question arises as to 
whether different nuclear retinoid receptors mediate the various biochemical and 
phenotypic changes induced in these melanoma cells by ATRA.  The availability 
of receptor-selective retinoids [30] provides one method to examine the relative 
importance of these different receptors in the regulation of B16 cell 
differentiation.  We found that of the receptor-selective retinoids evaluated, the 
RXR-selective compound SR11246 was most potent in inhibiting anchorage-
dependent growth, while SR11254 (RAR-selective) was most potent in inhibiting 
anchorage-independent growth.  In contrast,  Am580, an RAR-selective retinoid 
was more effective in inducing RAR mRNA and increasing PKC protein 
levels.  There was not a major difference in the ability of the various receptor-
selective retinoids to increase AP-1 transcriptional activity.   When we treated 
B16 cells with a combination of an RAR-selective and an RXR-selective retinoid 
we observed a synergistic induction of PKC.  This result suggests that for the 
regulation of this step of the differentiation pathway, RXR is not a "silent 
partner" in the receptor heterodimer, but can increase the response when 
occupied with ligand. 
 
MATERIAL AND METHODS 
Retinoids 
 All-trans -retinoic acid was purchased from Sigma Chemical Co. St. Louis, MO.  
9-cis -retinoic acid, Am580 (RAR-selective), SR11254 (RAR-selective), SR11246 
(RXR-selective) and SR11346 (RAR/RXR-selective) were synthesized as 
previously described [31, 32].  All retinoids were dissolved in DMSO and kept 
under nitrogen gas at -80oC.  Fresh stocks were prepared for each experiment.  
Manipulations with retinoids were performed under low light conditions to 
minimize photo-oxidation. 
Cell Culture 
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B16 mouse melanoma cells were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% heat-inactivated calf serum (Sterile 
Systems, Logan, UT), 2 mM L-glutamine, 2 mM sodium pyruvate, 50 U/ml 
penicillin G and 50 g/ml streptomycin sulfate.  Cells were incubated at 37oC in 
a 5% CO2/95% air, humidified atmosphere.  New cultures were initiated from 
frozen stock every 6 weeks in order to prevent phenotypic drift which can occur 
with prolonged culture of these cells. 
Anchorage-Dependent and -Independent Growth 
For monolayer growth studies, cells were seeded at 5 x 104 /well in 6 well tissue 
culture plates .  One day after seeding cells were refed with tissue culture media 
containing different concentrations of retinoids.  Cells were incubated with the 
retinoids for 48 h and then harvested, and cell number determined using a 
hemocytometer.  Each concentration of the different retinoids was assayed in 
triplicate dishes of cells and the entire experiment was repeated three times.  For 
anchorage-independent growth, 5,000 cells were mixed with 0.35% agarose in 
tissue culture media, and this mixture overlaid onto a 1% agarose base in 60 mm 
tissue culture dishes.  Lastly, a small amount of tissue culture media was added 
to cover the top layer.  All three layers contained retinoids at the concentrations 
indicated in the figures.  Every two days, the top layer of media with or without 
the appropriate concentration of retinoid was replenished  and after ten days of 
incubation the number of colonies containing greater than 25 cells was 
determined.  Each concentration of the different retinoids was assayed in 
triplicate dishes of the soft agarose cell suspension.  The entire experiment was 
repeated three times. 
Northern Blotting 
B16 cells were treated with the various retinoids for 24 h.  Control cell received 
the solublization agent DMSO.  Total RNA was isolated from cells using the TRI 
regent (Sigma, St. Louis, MO, according to the manufacturer's protocol.  30-40 g 
of total RNA was separated on 1% formaldehyde agarose gels and transfered to 
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Hybond NX membranes (Amersham, Arlington Heights, IL).  Following 
prehybrdization, blots were probed simultaneously for RAR and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  Full length GAPDH 
cDNA and a 615 bp EcoRI fragment from mouse RAR cDNA were used as 
probes.  These DNAs were labeled using the Prime-a-Gene labeling system 
(Promega, Madison, WI) according to the manufacturer's protocol.  
Unincorporated nucelotides were removed using QIAquick Nucleotide Removal 
kit (Qiagen, Chatsworth, CA).  Hybridization of the probes was performed at 68o 
C for 1 h using Express Hyb solution (Clontech, Palo Alto, CA).  Following 
hybridization, blots were washed for 40 min at room temperature in 0.3 M NaCl, 
30 mM sodium citrate (pH 7.0), 0.05% SDS followed by a 40 min wash at 50o C in 
15 mM NaCl, 1.5 mM sodium citrate (pH 7.0), 0.1% SDS.  Blots were then 
exposed to X-ray film at -80o C for various times in order to generate a signal in 
the linear range for densitometry (Molecular Dynamics, Sunnyvale, CA).  
Intensity of the RAR bands was normalized to the corresponding GAPDH band 
and the results expressed as a fold induction relative to the RAR mRNA signal 
in control cells. 
Western Blot Analysis of PKC 
Following a 24 h treatment with different concentrations of the various retinoids, 
B16 cells were washed twice with PBS, scraped into PBS and transferred on ice to 
a 15 ml centrifuge tube.  Cells were pelleted at 1000 x g for 5 min and 
resuspended in 200 ml of protein lysis buffer (20 mM Tris-HCl pH 7.5,  
containing 2 mM EDTA, 1% Triton X-100, 2 mM dithiothreitol, 50 mM NaF, 10 
mM Na HPO4, 1 g/ml leupeptin, 1 g/ml pepstatin, 50 g/ml aprotinin, 87 
g/ml PMSF).  Cells were vortexed and disrupted by sonication.  The cell lysate 
was transferred to 1.5 ml microfuge tubes and centrifuged for 5 min at 12,000 x g.  
Protein was determined by the BCA method (Pierce Chemical Co, Rockford, IL) 
according to the manufacturer's instructions.  Bovine serum albumin was used to 
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construct a standard curve.  Equal amounts of protein were separated by SDS-
PAGE on 10% polyacrylamide gels and then electrophoretically transferred onto 
nylon membrane (Hybond C, Amersham, Chicago, IL) using a semi-dry blotting 
apparatus (Bio-Rad, Hercules, CA).  The nylon membrane was incubated with 
5% non-fat dry milk overnight at room temperature.  The membrane was then 
washed 3x with TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Tween 20) 
for 5 m each, at room temperature.  The membrane was then incubated with a 
1:500 dilution of antibody to PKC (UBI, Saranac Lake, NY) for 1 h at room 
temperature.  Subsequently, the membrane was washed as described above and 
further incubated with horseradish peroxidase conjugated goat-anti-mouse IgG 
at room temperature for 1 h.  The membrane was washed three times with TBST 
and developed using the ECL kit (Amersham, Chicago, IL).   
 
 
Transient Transfection and AP-1 Activity 
B16 cells were transfected using the lipofectin reagent with 1.5 g of pGL-2-AP-1 DNA 
or the pGL-2 vector alone (1.0 g) + 0.5 g of SV40- gal DNA to correct for transfection 
efficiency as described previously [27].  After an overnight incubation the transfection 
medium was removed, and the cells incubated with different concentrations of the 
various retinoids as indicated in the results.  Cells were harvested 48 h after transfection 
and assayed for luciferase and-galactosidase activity using kits from Promega 
(Madison, WI).  Luciferase activity in each individual sample was normalized by the 
amount of -galactosidase activity in the same sample, in order to correct for the 
transfection efficiency between dishes of cells.  All transfections were performed in 
triplicate dishes and the experiments were repeated 3-5 times. 
 
RESULTS 
Transcriptional activation activity of retinoids 
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Retinoids bind and activate the transcriptional activity of their nuclear receptors.  
We tested the ability of various retinoids to stimulate the transcription of a 
reporter gene containing a retinoid response element.  Both ATRA and 9CRA 
had similar potency for activating RAR,  and  (Table 1).  However, 9CRA was 
much more effective than ATRA in activating RXRThis agrees with the poor 
binding affinity of the RXRs for ATRA.  Activation of RXR by ATRA at higher 
concentrations was probably due to its metabolism to 9CRA.  At  10-8M,  AM580 
specifically activates RAR , however, at higher concentrations,  it also activates 
RAR.  SR11254 has greater selectivity for activating RAR vs all the other 
receptors, while SR11246  is the most specific retinoid with activity mostly 
limited to activating RXR.  SR11346 is an interesting retinoid, since it activates 
both RAR and RXR, with a somewhat greater sensitivity for RXR activation.  
Based on these results we compared the effectiveness of the various retinoids for 
inhibiting anchorage-dependent and independent growth, induction of RAR, 
and PKC and increasing AP-1 transcriptional activity at 10-7M concentration.  
The choice of this concentration was a comprimise between inducing a 
measureable change in the parameter under investigation and retaining receptor 
selectivity. 
 


Regulation of anchorage-dependent growth by receptor-selective retinoids.   
We have previously found that ATRA inhibited the growth of B16 mouse 
melanoma cells in a concentration-dependent manner [24].  Using both pan-
RAR/RXR agonist (9CRA) and receptor-selective retinoids, we determined 
whether any of the receptor-selective retinoids played a more dominant role in 
mediating the inhibition of anchorage-dependent growth.  At the highest 
concentration tested (1 M) we found that ATRA gave the greatest amount of 
inhibition of cell proliferation (Fig. 1 panel A).  Among the receptor-selective 
 10 
retinoids,  SR11246 (RXR-selective) gave the greatest inhibition of growth (60% of 
control) at 1 M concentration (Fig. 1 panels B and C).  When all of the retinoids 
were compared at 10-7M concentration,  only ATRA, 9CRA, and SR11246 
significantly inhibited cell proliferation (Fig. 1, panel D).  
 
Effect of retinoids on anchorage-independent growth 
Normal somatic cells require substrate attachment in order to proliferate, 
whereas tumor cells acquire the ability to replicate without attachment to a 
substrate.  This property of transformed cells is perhaps the best indicator of 
tumorigenicity.  ATRA inhibits anchorage-independent growth of a number of 
tumor cell lines [33, 34].  We measured anchorage-independent growth in B16 
cells by their ability to form spheroid colonies containing greater than 25 cells in 
0.35% agarose.  All of the retinoids inhibited anchorage-independent growth in a 
concentration-dependent manner (Fig. 2).  When compared at an equimolar 
concentration (10-7 M), all the retinoids significantly inhibited colony formation 
in soft agarose (Fig. 2, panel D).  Overall, ATRA was the most potent compound 
at this concentration (65% inhibition of colony formation), while among the 
receptor-selective retinoids, SR11254 (RAR-selective) was somewhat more 
effective than Am580 (RAR-selective), with both of these compounds being 
considerably more effective than either SR11246 (pan-RXR) or SR11346 (pan 
RXR, RAR).
 
 
 
Induction of RAR mRNA by retinoids   
Induction of RAR is one of the early responses to ATRA treatment of B16 cells 
[28].  An increase in the level of this message can be detected within 1 h of 
treatment.  RAR mRNA was induced at least 15-fold by the lowest 
concentration of ATRA tested (1 nM, Fig. 3A).  This particular response was 
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already maximal at 10 nM of ATRA.  9CRA required a concentration of 100 nM 
to reach the maximal induction of RAR mRNA (18-fold, Fig. 3A).  Among the 
receptor selective retinoids, only AM580 (RAR-selective) was able to achieve a 
substantial increase in the RAR mRNA.  When compared at a concentration of 
10-7M, the following ranking for inducing RAR mRNA was observed (Fig. 3B): 
ATRA> 9CRA >> AM580 >> SR11254 > SR11346 > SR11246. 
 
Increased expression of PKC protein by retinoids   
ATRA induces a large increase in PKC mRNA and protein [35].  This increase in 
PKC appears to play an important role in the ATRA-induced differentiation 
pathway since overexpression of PKC in untreated cells can mimic several of 
the properties of ATRA-treated cells, while down-regulation of PKC by phorbol 
esters antagonizes the ATRA-induced differentiation [26].  To determine the role 
of RAR and RXR in PKC induction, cells were treated for 24 h with different 
concentrations of the various retinoids and PKC protein levels were determined 
by Western blots.  The most effective retinoid was ATRA,  which induced an 6-
fold increase in PKC at a concentration of 1 nM (Fig. 4, panel A).  Surprisingly, 
the RAR/RXR pan agonist 9CRA was not as effective, requiring a concentration 
of 100 nM to achieve an 8-fold induction of PKC.  However, at the maximum 
concentration tested (1 M), 9CRA resulted in the highest fold increase in PKC 
(9-fold).  Among the receptor selective retinoids, at concentrations where 
specificity is maintained (10-7M), Am580 (RAR selective) was the most effective 
and at 1 nM induced a 3-4 fold increase in PKC (Fig. 4A). 
 
 
 
Increase in AP-1 activity by retinoids   
We have reported that ATRA increases AP-1 transcriptional activity in B16 
mouse melanoma cells [27].  This finding is in contrast to other cell types where 
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RA inhibits AP-1 DNA binding and transcriptional activity [36-38].  To examine 
which receptors might mediate this response we transfected B16 cells with an 
AP-1 reporter plasmid and then treated the transfected cells for 24 h with 
different concentrations of the various retinoid analogs.  9CRA was the most 
effective compound, inducing an 2.6-fold increase in AP-1 activity at a 
concentration of 10 –7 M (Fig. 5B).  In contrast to other retinoid-induced changes, 
there was not a significant difference between any of the receptor-selective 
retinoids in their ability to increase AP-1 activity (Fig. 5A and B).   
 
Interaction between RAR and RXR ligands 
It has been reported that RXR is a "silent partner" in the RXR/RAR heterodimer 
which activates gene transcription [39].  However, since several recent reports 
have shown that liganded RXR increases the extent of gene transcription induced 
by the liganded RAR partner [40-42],  we determined whether liganded RXR 
would further increase the retinoid induction of PKC.  Cells were treated for 24 
h with various retinoids alone or in combination (Fig. 6).  Among the receptor-
selective retinoids, Am580 (RAR) was most effective in inducing PKC, 
verifying our earlier findings (Fig. 4).  While the RXR agonist SR11246 did not 
increase the level of PKC, it did enhance the induction due to ATRA (column 2 
vs 8), Am580 (column 4 vs 9), and SR11254 (RAR-selective) (column 5 vs 10).   
 
DISCUSSION 
 B16 cells constitutively express RAR  and RXR  Treatment of the 
cells with ATRA induces the expression of RAR [28].  Thus the question arises 
as to whether these different receptors mediate different functions during the 
ATRA-induced growth arrest and differentiation of B16 melanoma cells.  The 
question of receptor function has been addressed using targeted gene disruption 
in transgenic animals [43-45].  The results of these studies initially lead to the 
concept of total receptor redundancy since inactivation of any one of the retinoid 
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nuclear receptors did not cause any major defects in the development of the 
fetuses.  However, recent experiments have provided evidence that some 
functional redundancy between RARs may be an artifactual consequence of gene 
knock-outs [46, 47].  Also disruption of either RAR or RARin F9 
teratocarcinoma cells resulted in alterations in ATRA-induced differentiation and 
ATRA metabolism that were specific to the receptor which was inactivated[48]. 
 Another approach to investigating nuclear retinoid receptor-specific 
functions is the use of retinoid analogs which have a greater affinity for binding 
and activating a specific class or subtype of receptor.  Conformationally 
restricted analogs of ATRA were synthesized and shown to exhibit receptor-
selective activation profiles using the TREpal reporter plasmid [30, 32]. Therefore 
we investigated the effect of receptor-selective retinoids on growth and various 
biochemical changes associated with ATRA-induced differentiation of B16 
melanoma cells.  
 Both ATRA  and  9CRA treatment of B16 cells resulted in a concentration-
dependent inhibition of anchorage-dependent growth.  Interestingly, when 
receptor-selective retinoids were compared at 0.1 M concentrations, the RXR-
selective ligand SR11246 was the most effective analog for inhibition of growth 
and also caused the greatest level of inhibition at the maximal concentration used 
in these experiments.    This particular retinoid shows high selectivity for 
activating RXR in transient transfection assays using the TREpal response 
element (Table 1), and we have recently shown that it is very effective in 
activating transcription of a reporter gene containing a DR-1 type RXRE (Niles 
and Desai, unpublished data).  RXR-selective retinoids have been shown to be 
relatively poor inhibitors of cell proliferation in various tumor cell lines [49-51].  
However, these retinoids enhanced apoptosis in HL-60 cells [52],  significantly 
inhibited the proliferation of three different human prostate cancer cell lines [53] 
and inhibited the growth of ATRA-resistant human breast cancer cells [54].  It 
should be noted that we did not observe an increase in apoptosis in B16 cells 
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treated with any retinoid (data not shown).  The mechanism by which liganded 
RXR can inhibit B16 cell growth is not known.  RXR agonists alone can not 
activate transcription of the RXR:RAR heterodimer due to steric blockage of the 
ligand binding site by the RAR partner.  Ligand binding to RAR removes this 
block, allowing RXR to bind ligand [55].  In certain RXR heterodimers binding of 
ligand to either partner can activate transcriptional activity [56, 57].  Thus it is 
possible that other RXR heterodimers are responsible for SR11246 induced 
growth inhibition in B16 cells. 
 All retinoids tested were capable of inhibiting anchorage-independent 
growth (soft agar colony formation).  Among the receptor-selective retinoids, 
SR11254 (RAR-selective) was somewhat more effective than AM580.  The least 
effective retinoids were SR11246 and SR11346 (RXR and RXR/RAR-selective 
respectively).  Thus in contrast to anchorage-dependent growth, RXR appears to 
play a less important role in suppressing anchorage-independent growth. 
 One of the early changes in RA-induced differentiation of B16 cells is a 
direct stimulation of RAR gene expression [28].  ATRA was quite potent in 
inducing the expression of RAR mRNA (Fig.3A).  9CRA was also quite effective 
in inducing RARmRNA, but required higher concentrations than ATRA and 
did not reach the maximal fold induction achieved by ATRA.  Among the 
receptor-selective retinoids, only Am580 was able to induce a major increase in 
RAR mRNA levels.  These results suggest that in B16 cells the RAR receptor 
plays the major role in the induction of the RAR receptor.  
 We previously reported that ATRA treatment of B16 cells results in a 
marked increase in PKC mRNA and protein levels and that this change plays 
an important role in retinoid-induced growth arrest and differentiation [35, 26].  
When receptor-selective retinoids were tested for their ability to induce PKC 
protein, Am580, the RAR-selective retinoid, was most potent, being equally 
effective as ATRA at 0.1 M concentration.  Other laboratories have reported that 
RAR appears to play a more prominant role in both growth arrest and specific 
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gene induction in human breast cancer cells [32, 58]. We have previously shown 
that the induction of PKC mRNA by ATRA is blocked by inhibitors of protein 
synthesis, indicating that another retinoid-induced protein is required for the 
increase in PKC expression.  Since Am580 is the only receptor-selective retinoid 
which significantly induced RAR, we favor the hypothesis that RAR activates 
transcription of the RAR gene and this receptor (RAR) in turn induces 
expression of the PKC mRNA and protein.     
 We have recently reported that, unlike other cell types, treatment of B16 
cells with ATRA does not inhibit AP-1 activity, but instead stimulates the activity 
of this transcription factor complex [27].  Differentiation of melanoma cells has 
been found to be associated with an increase in AP-1 activity [59].  All of the 
receptor- slective retinoids stimulated AP-1 activity about 1.7 - 1.9 fold at 0.1 M 
concentration.  Thus it appears that there is no receptor selectivity for stimulating 
AP-1 activity.  The mechanism by which retinoids can increase AP-1 
transcriptional activity in B16 cells is at present unknown.   
 Previous work has suggested that the RXR:RAR heterodimer functions 
optimally when only the RAR site is bound by ligand [39].  In contrast, other 
investigators have reported that maximal stimulation of specific gene expression 
or biologic functions, such as differentiation, require ligand bound to each 
partner of the heterodimer [40, 42].  To investigate this question we examined 
combinations of receptor-selective retinoids on the induction of PKC protein.  
At the concentrations used in these experiments, the RXR agonist SR11246 did 
not increase PKC, but when it was combined with an RAR agonist (ATRA, 
Am580 or SR11254) a further enhancement of PKC induction was achieved.  
These results suggest that activation of RAR via ligand binding is obligatory for 
induction of PKC, and ligand binding to RXR is not required.  However, ligand 
binding to RXR can further enhance the expression of PKC.  It has been shown 
that this heterodimeric subordination of RXR AF-2 acitivity is due to an allosteric 
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effect of unliganded RAR on the interaction surface for co-activators in the RXR 
molecular [60] 
 In summary, our results suggest that different nuclear retinoid receptors 
have different roles in mediating retinoid-induced growth arrest and 
differentiation of B16 mouse melanoma cells.  Although one could make the 
argument that differences observed in these experiments could be due to altered 
metabolic rates of the various retinoids, two types of results suggest that this is 
not the case.  First, treatment of cells transfected with an RARE –reporter gene 
with receptor-selective retinoids results in an in vivo activation of RAR 
transcriptional activity which correlates with their in vitro binding to the 
different RAR/RXR.  Second, the biochemical/cellular changes measured in this 
study did not all have the same pattern for retinoid selectivity, which would be 
expected if only altered rates of retinoid metabolism were responsible for the 
observed changes.  The RXR appear to be involved in retinoid-induced inhibition 
of anchorage-dependent growth while the RAR, especially RAR , are the 
primary players in anchorage-independent growth.  In terms of induction of 
specific genes, the RAR, especially RAR, appear to play the dominant role.  
Retinoid-induced increase in AP-1 transcriptional activity did not appear to 
depend on any specific retinoid receptor preference and thus occupany of either 
RAR or RXR with ligand may be sufficient to initiate this response.  Lastly it is 
clear that, at least for induction of PKC, RXR is not a "silent" partner of the 
heterodimer, since occupancy of this receptor with ligand maximized the 
induction of this protein.  These results support the concept that retinoid analogs 
can be designed to target specific cellular functions thus enhancing the 
therapeutic usefulness of retinoids. 
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FIGURE LEGENDS 
 
Fig. 1.  The effect of various retinoids on B16 mouse melanoma anchorage-
dependent growth. 
 
 B16 cells were seeded at 5 x 104 /60 mm tissue culture dish.  After a 24 h 
attachment period, cells were refed with growth medium containing the 
indicated concentrations of retinoids.  After an additional 48 h of incubation, cells 
were harvested and their number determined with a hemocytometer.  A, B, and 
C are the concentration -response curves for growth inhibition plotted as a % of 
control cells (these cells only received the solubilization vehicle DMSO).  The 
error bars represent the SEM of triplicate dishes of cells at each concentration of 
retinoid.  Panel D compares the relative growth inhibition of all the retinoids 
tested at 10-7M.  (*) : means were significantly different from control at p < 0.05,  
using ANOVA followed by Newman-Keuls multiple comparisons.  The 
experiment was repeated two additional times with similar results 
 
 
Fig. 2.  Inhibition of B16 anchorage-independent growth by retinoids. 
 
 B16 cells (5,000) were mixed with 0.35% agarose in growth media and 
overlaid onto a 1% agarose base in 6 well (35 mm) plates.  All layers contained 
the indicated concentrations of retinoids.  At the end of ten days of incubation 
the number of colonies containing greater than 25 cells (colonies > 3 mm 
diameter) was determined.  Panels A, B, and C depict the average number of 
colonies,  with the error bars representing the SEM of triplicate dishes of cells for 
each concentration of retinoid tested.  Data points without apparent error bars 
indicate that the SEM was less than the symbol.  Panel D compares the inhibitory 
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effect of all retinoids tested at 10-7M concentration.  Notice that all retinoids are 
significantly different from control (*) at p < 0.05 using ANOVA followed by 
Neuman-Keuls multiple comparisons.  This experiments was repeated two 
additional times with similar results. 
 
Fig. 3.  Induction of RAR mRNA by retinoids 
 
 B16 cells were grown to about 70% confluence in 100 mm tissue culture 
dishes, then refed with culture medium containing the indicated concentrations 
of the various retinoids, and incubated for 24 h.  Cells were then harvested and 
processed for RNA purification and Northern blotting as described in Methods.  
A.  Relative fold induction of RAR mRNA by different concentrations of 
retinoids.  Autoradiograms from the Northern blots were quantitated using a 
Molecular Dynamics laser densitometer and after correcting for the internal 
standard GAPDH a relative increase in RAR mRNA was calculated using 
control cells treated only with solubilization vehicle (DMSO).  The data is plotted 
as the average of three separate experiments +/- SEM (error bars).  B.  Relative 
fold induction of RAR mRNA by various retinoids at 100 nM concentrations 
and representative Northern blot (insert).  Data is presented as the mean +/- 
SEM (error bars) from three separate experiments. 
 
Fig. 4.  Increase in PKC protein levels in B16 cells treated with different 
retinoids. 
 
 Cells were seeded at 2 x 105/100 mm tissue culture dish and allowed to 
attach for 24 h.  They were then refed with growth medium containing the 
retinoids at the concentrations indicated in the figure.  After a 24 h incubation 
with these compounds, cells were harvested and assayed for the relative level of 
PKC by Western blotting as described in Methods.  Autoradiograms were 
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quantitated using a Molecular Dynamics laser densitometer and plotted as OD 
units.  This experiment was repeated three additional times with similar results. 
 
 
 
 
 
Fig. 5.  AP-1 transcriptional activity in B16 cells treated with different retinoids. 
 
 Cells were co-transfected with an AP-1-luciferase reporter plasmid and a 
plasmid encoding -galactosidase (to correct for transfection efficiency) as 
described in Methods.  After an overnight incubation, the transfection medium 
was removed and the cells refed with growth medium containing different 
concentrations of retinoids.  Cells were harvested 48 h after transfection and 
assayed for luciferase and-galactosidase activities.  The data are corrected for -
galactosidase activity and presented as the average luciferase activity +/- the 
SEM (error bars) from triplicate dishes of transfected cells.  The entire experiment 
was repeated three additional times with similar qualitative results.  None of the 
retinoids increased luciferase expression in cells transfected with the luciferase 
plasmid lacking the AP-1 element (data not shown) 
 
 
Fig. 6.  The effect of retinoids alone and in combination on induction of PKC 
protein in B16 cells. 
 
 Cells were seeded at 2 x 105  in 100 mm tissue culture dishes.  After a 24 h 
attachment period, cells were refed with growth medium containing the various 
retinoids alone or  the combinations listed.  Single retinoids were present at a 
concentration of 1.0 x 10-7 M; retinoid combinations totaled 2 x 10-7 M (each 
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retinoid component was at 1.0 x 10-7 M).  The data are presented as the mean 
induction of PKC as determined by densitometric scans of the autoradiograms 
from three separate experiments.  The error bars represent the SEM of the three 
experiments.  The insert is a Western blot of PKC levels from a representative 
experiment.
